Please login to the form below

Not currently logged in
Email:
Password:

Patient

This page shows the latest Patient news and features for those working in and with pharma, biotech and healthcare.

Merck & Co halts development of potential COVID-19 drug MK-7110

Merck & Co halts development of potential COVID-19 drug MK-7110

The timescale for potential clinical development, coupled with technical, clinical and regulatory uncertainties have factored into Merck &Co’s decision to discontinue the MK-7110 programme for patients hospitalised with ... 19. The company also

Latest news

  • Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US

    In the phase 3 BLAZE-1 trial, the combination of bamlanivimab and etesevimab significantly reduced the risk of hospitalisations and death in high-risk COVID-19 patients. ... The CHMP also recommended that bamlanivimab can be used as a monotherapy for the

  • Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses

    months when compared to Sanofi’s Aubagio (teriflunomide) in a subgroup of newly diagnosed, treatment-naive patients with relapsing multiple sclerosis (RMS). ... The PIRA analysis also showed that over 50% of disability worsening events experienced by

  • Indigo Medical joins imc group Indigo Medical joins imc group

    With the addition of Indigo, imc group will now offer services for clients across seven core divisions, including medical &scientific content, publications, digital &creative, insights &consulting, patient engagement, meetings &events and

  • Making social sexy Making social sexy

    And this isn’t completely new ground. Brands like Ella One and Viagra Connect have shown that social media can work for industry and patients. ... And they’ve done it in a grown-up way that focuses on the patient’s experience, not childish humour.

  • GSK discontinues two feladilimab trials in head and neck cancer GSK discontinues two feladilimab trials in head and neck cancer

    In a statement issued today, GSK said that following a recommendation by the Independent Data Monitoring Committee, it will stop enrolling patients in the phase 2 INDUCE-3 trial – including discontinuing ... The mid-stage study is evaluating

More from news
Approximately 206 fully matching, plus 6,166 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 95 fully matching, plus 966 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 488 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 374 fully matching, plus 1,023 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics